INDEX

Note: Page numbers of article titles are in boldface type.

Abdominal vasculature, ultrasound anatomy of, 321
Acid-base imbalance, and hepatic encephalopathy, 345
Albumin, copper-binding by, 401
Aldosterone, for biliary cirrhosis, 382
Alkaline phosphatase, serum, in cholestasis, 259-260
Amino acids, consumption of, in liver disease, 496
metabolism of, and hepatic encephalopathy, 340-341
Aminotransferases, in liver disease, 258
Ammonia. See also Hyperammonemia.
generation of, in liver disease, 488
role in hepatic encephalopathy, 339-340
serum, tests of, 263-264
Ampicillin, for hepatic encephalopathy, 347
Anemia, in liver disease, 266
with liver cancer, 428
Anorexia, in liver disease, management of, 494
Anti-inflammatories, for copper-associated hepatopathies, 410
Antibiotics, for hepatic encephalopathy, 345-347
in acute liver failure, 453
for suppurative cholangitis/cholangiohepatitis, 377
Arginine, dietary, in hepatic encephalopathy, 349
Arteriovenous malformation, hepatic, appearance of, 333
Ascites, in biliary cirrhosis, 382
in portal hypertension, 466-468
treatment of, 476-480
medical, 476-478
surgical, 478-480
with generalized hepatomegaly, 308
Ascorbic acid, for copper-associated hepatopathies, 406
Autoimmune chronic active hepatitis, 392-393
Azathioprine, for long-term hepatitis, 395
Bacterial infections, and acute liver failure, 440
Baker biopsy punch, 287
Bedlington terrier, chronic active hepatitis in, 391-392
copper-associated hepatopathy in, 411-412
Benzodiazepines, endogenous, in hepatic encephalopathy, 341-343
Bicarbonate, for hepatic encephalopathy, 346
Bile acids, in hepatobiliary disease, 503-517
in liver disease diagnosis, 505-507
metabolism of, 504-505
physicochemical properties of, 504-505
tests of, 262-263
therapeutic potential of, 509-511
toxicity of, 507-509
Bile sludging, prevention of, bile acids for, 510
Biliary carcinoma, prevalence of, 422
radiographic appearance of, 426
treatment and prognosis in, 431
Biliary cirrhosis, 381-383
Biliary obstruction, causes of, 329
cholangiography of, 317
Biliary tract, diseases of, 327-331
Bilirubin, conjugated, threshold for, 262
tests of, 261
Biopsy, percutaneous needle, for acute liver failure, 448
Biopsy guns, automated, for liver biopsy, 282
Biopsy needle, in liver, sonogram of, 283
Biopsy instrument, for liver biopsy, 282-283
Bleeding profiles, in liver disease, 265
Blood products, for hemorrhage, in acute liver failure, 454
Cancer, hepatic, metastatic, radiographic appearance of, 426
Carbohydrate, metabolism of, in liver disease, 485–486
Cardiovascular system, support of, in acute liver failure, 449
Cat(s), hepatic neoplasia in, 419–435
urea cycle of, 369
with liver disease, homemade diets for, 495
Cerebral edema, in fulminant hepatic failure, 351
Chelating agents, for copper-associated hepatopathies, 408–410
Chemical agents, and acute liver failure, 438–439
Chenodeoxycholate, for cholelithiasis, 509–510
Chenodeoxycholic acid, toxicity of, 509
Cholangiohepatitis, feline, 375–385
lesions of, 299
nonsuppurative, 379–380
portal fibrosis of, 380
suppurative, 376–379
Cholangitis, emphysematous, 311
lesions of, 299
nonsuppurative, 379–380
suppurative, 376–379
Cholecystitis, acute, ultrasound scan of, 328
Cholecystography, 315–317
Cholelithiasis, 328–329
bile acids for, 509–510
Cholescintigraphy, biliary, in suppurative cholangitis/cholangiohepatitis, 377
Cholestasis, and hyperbilirubinemia, 262
bilirubinemia, 262
enlargement of, 259–260
prevention of, by ursodeoxycholate, 512
Cholesterol, in liver disease, 265–266
Cirrhosis, biliary, 381–383
hepatic, ultrasound scan of, 323
Coagulation studies, in acute liver failure, 444–445
in liver disease, 265
Coagulopathies, in feline idiopathic hepatic lipidosis, 365
Cocker spaniel, chronic active hepatitis in, 392
Colchicine, for long-term hepatitis, 395
Common bile duct, dilatation of, 330
Copper, accumulation of, and liver disease, 399
breeds associated with, 400
chelators of, 410
distribution of, 401
food content of, 400, 406
hemostasis of, 401
metabolism of, 400–402
abnormal, 402–403
in liver disease, 490
toxicity of, 403
transport in body, 402
Copper-associated hepatopathies, 399–417
clinical picture of, 403–404
diagnosis of, 404–405
emergency treatment of, 411
guidelines for therapy, 414–415
treatment of, 405–411
Copper storage disease, and acute liver failure, 441
Copper toxicity, in liver disease, 498
Corticosteroids, for biliary cirrhosis, 383
for chronic hepatitis, 394–395
for suppurative cholangitis/cholangiohepatitis, 377
Cystic duct, dilatation of, 330
Dehydrocholate, for bile sludging prevention, 510
Diazepam, for hepatic encephalopathy, 346
Diet, for copper-associated hepatopathies, 406–408
for feline idiopathic hepatic lipidosis, 362–366
calculation of, 364
for hepatic encephalopathy, 348–351
for chronic hepatitis, 395
Diuretics, for ascites, in portal hypertension, 476
for biliary cirrhosis, 382
Doberman pinscher, chronic active hepatitis in, 391
copper-associated hepatopathy in, 413–414
Dog(s), chronic active hepatitis in, 393
copper-associated hepatopathies in, 399–417
hepatic neoplasia in, 419–435
with liver disease, homemade diets for, 495
Drugs, and acute liver failure, 438–440
for feline idiopathic hepatic lipidosis, 365
Electrolytes, imbalance of, and hepatic encephalopathy, 345
Enalopril, for biliary cirrhosis, 382
Encephalopathy, hepatic, 337–355. See also Hepatic encephalopathy.
Enemas, for hepatic encephalopathy, 346
Energy, requirement for, in liver disease, 491–492
Erythrocytes, abnormalities of, in liver disease, 266
Extrahepatic shunt, appearance of, 332–333

Fat, dietary, in hepatic encephalopathy, 350
metabolism of, in liver disease, 486–487
Fatty acids, consumption of, in liver disease, 497
in feline idiopathic hepatic lipidosis, impaired oxidation, 369–371
increased mobilization, 367–368
Feeding management, in liver disease, 494–496
Fine-needle aspiration, for acute liver failure, 447–448
Fluid therapy, for acute liver failure, 451–452
for hepatic encephalopathy, 346
Flumazenil, for hepatic encephalopathy, 453–454
Foods, copper content of, 400, 406
Fungal infections, and acute liver failure, 440
Gastrointestinal bleeding, and hepatic encephalopathy, 344
in acute liver failure, protective agents for, 454–455
Glucose, for hepatic encephalopathy, 346
serum, in liver disease, 264
Glutamate, in hepatic encephalopathy, 341
Hemangiosarcoma, hepatic, 326
metastatic, 421
radiographic appearance of, 426
liver, 423
treatment and prognosis in, 431
Hematemesis, in feline idiopathic hepatic lipidosis, 365
Hematologic abnormalities, in liver cancer, 428
in liver disease, 266
Hematomas, hepatic, 325
Hemorrhage, in acute liver failure, management of, 454–455
Hemostasis, in liver disease, 265
Hepatic arteriovenous malformations, imaging of, 314
Hepatic aspiration, 275–291
Hepatic coma, 351–352
Hepatic conjugation, tests of, 261–264
Hepatic disease, diffuse, 322–325
focal, 325–327
Hepatic encephalopathy, 337–355
amino acid metabolism and, 340–341
clinical findings in, 337–338
endogenous benzodiazepines in, 341–343
gamma-aminobutyric acid in, 341
glutamate in, 341
grading system for, 339
in acute liver failure, management of, 452–454
in liver disease, recommendations for, 496–497
in portal hypertension, 466
treatment of, 475
pathogenesis of, 338–343
predisposing causes of, 343–345
role of ammonia in, 339–340
therapy of, 343–351
antibiotic, 345–347
diet, 348–351
Hepatic lipidosis, 324
feline, 295
and acute liver failure, 441
idiopathic, 357–373
clinical findings in, 358–359
comparative aspects of, 357–358
diagnostic imaging of, 359–362
in liver disease, management of, 497
laboratory findings in, 359–362
lipoprotein abnormalities in, 368–369
pathophysiology of, 366–371
therapy for, 362–366
dietary, 362–364
drug, 365
types of, 358
process of, 299
Hepatic neoplasia, in dog and cat, 419–435. See also under Liver.
Hepatitis, acidophil cell, canine, 390
and acute liver failure, 441
chronic, active, 388
autoimmune, 392–393
in dogs, 393
leptospirosis-associated, 389
lobular, 387–388
progressive, 387
copper-associated, 390–391
lesions of, 299
lobular-dissecting, 393
long-term, 387–398
active, 300
breed-associated, 391–392
diagnosis of, 394
drug-associated, 390
etiology of, 388–389
Hepatitis (Continued)

infectious canine hepatitis virus-associated, 389
management of, 394–396

Hepatobiliary disease, bile acids in, 503–517

Hepatocellular carcinoma, classification of, 421
gross appearance of, 422
radiographic appearance of, 426–427
treatment and prognosis in, 430–432

Hepatocellular damage, and hyperbilirubinemia, 261

Hepatolenticular disease, copper metabolism in, 402

Hepatoma(s), 301–302
in dog, 309

Hepatomegaly, generalized, canine, 308
in biliary cirrhosis, 381
with multiple mineralizations, 311

Hepatopathies, copper-associated, 399–417
breed variation in, 411–414
Bedlington terriers, 411–412
Doberman pinschers, 413–414
Skye terriers, 413
West Highland white terriers, 412–413
clinical picture of, 403–404
diagnosis of, 404–405
emergency treatment of, 411
guidelines for therapy, 414–415
treatment of, 405–411

Hepatotoxicity, copper-associated, 399

Hepatotoxins, and acute liver failure, 438–440

Hyperammonemia, in liver disease, recommendations for, 496
in portal hypertension, 470

Hyperbilirubinemia, tests of, 261

Hypercalcemia, with liver cancer, 428–429

Hypernatremia, in acute liver failure, management of, 452

Hypertension, portal, diagnosis of, 331

Hyperthyroidism, feline, case study of, 266–267

Hyperventilation, for cerebral edema, 352

Hypoglycemia, in liver disease, 264
with liver cancer, 428

Hypokalemia, in acute liver failure, management of, 451

Hypoproteinemia, in liver disease, 264

Immunomodulation, by ursodeoxycholate, 512

Infection, and hepatic encephalopathy, 344
Infectious agents, and acute liver failure, 439–441

Infectious canine hepatitis virus, and long-term hepatitis, 389

Ischemia, massive, and acute liver failure, 441

Kidney, ultrasound scan of, 320

Labrador retriever, chronic active hepatitis in, 392

Lactulose, for hepatic encephalopathy, 346–348
in acute liver failure, 453

Laparotomy, exploratory, in acute liver failure, 448

Leiomyosarcoma, hepatic, metastatic, radiographic appearance of, 427

Leptospirosis, and chronic active hepatitis, 389

Leukocytosis, in liver disease, 266
neutrophilic, with liver cancer, 428

LeVeen shunt, for ascites, in portal hypertension, 479

Lipid(s), metabolism of, in liver disease, 486–487

Lipidosis, hepatic, feline, idiopathic, 357–373. See also Hepatic lipidosis.

Liver, aspiration of, 275–291
biochemical tests of, categories of, 257
biopsy of, 275–291
exploratory celiotomy and, 285–289
biopsy punch technique, 287
excisional biopsy via lobectomy, 288–289
ligature techniques, 286–287
perioperative considerations, 286
wedge resection or partial lobectomy technique, 287–288
handling of sample, 290
in biliary cirrhosis, 381–382
in feline idiopathic hepatic lipidosis, 361–362
in nonsuppurative cholangitis/cholelangiohepatitis, 379–380
in portal hypertension, 471
in suppurative cholangitis/cholelangiohepatitis, 376
indications for, 275
interpretation of, 293–303
laparoscopic, 285
postbiopsy care in, 289–290
prebiopsy considerations in, 276–277
liver size, 277
patient’s physical status, 276
risk for hemorrhage, 276
risk for impaired wound healing, 277
INDEX 523

specialty needles for, cost of, 282
specimen from, 293–294
techniques of, 278–289
blind, 278
fine-needle, 278
hepatic aspirate, 278
keyhole, 279–281
needle, 279–281
percutaneous, 278
ultrasound-guided, 281–285
transjugular, 289
transthoracic, 285
carcinoids of, 423
centrilobular necrosis and hemorrhage in, 297–298
circulation of, 461–464
anatomy and physiology, 461–462
pathophysiology, 462–464
cirrhosis of, 300–301
ultrasound scan of, 323
clinicopathologic evaluation of, 257–273
case studies in, 266–271
cholestatic enzymes, 259–260
hepatocellular enzymes, 258–259
degenerative or metabolic changes in, 298–299
disease of. See Liver disease.
ventration into thoracic cavity, 312
failure of, 437–460. See also Liver failure.
fibrosis of, 300–301
hematomas of, 301–302
hyperplastic nodules of, 325
radiographic appearance of, 426
imaging of, 305–335
cholecystography, 315–317
radiographic, 305–307
normal anatomy, 306
size, shape, and margination, 306–307
with radiographic contrast, 312–315
peritoneography, 313
portography, 313–314
with radiology and ultrasound, 305–335
with ultrasoundography, 317–327
islet cell carcinoma of, gross appearance of, 422
lesions of, diagnostic expectations in, 296–298
inflammatory, 299–300
location and categorization of, 294–296
zonal, 296
lobectomy of, with surgical stapler, 288
necrosis of, canine, case study of, 269
causes of, 300
neoplasia of, 419–435
adjuvant chemotherapy for, 432
biopsy procedures for, 429–430
breed, age, and sexual predilections in, 421
etiology of, 424
gross distribution of, 423
incidence and prevalence of, 419
laboratory findings in, 428–429
metastatic, 327
pathology of, 421–424
presenting signs and findings in, 424–425
primary, 326
radiographic and ultrasonographic findings in, 425–428
surgery for, 429–430
treatment and prognosis in, 430–432
tumor types in, 419–421
position of, changes in, 312
radiopacity of, alterations in, 307–311
regeneration of, 301–302
secretion of, tests of, 261–264
small, in dog, 310
synthesis by, tests of, 264–266
ultrasound anatomy of, 319–322
uptake by, tests of, 261–264
vasculature of, abnormalities of, 331–333
venous congestion of, 331
Liver disease, diagnosis of, bile acids in, 505–507
dietary recommendations for, 491–496
diffuse, 322–325
homemade diets for, 495
in cats, drugs for, 378
laboratory data in, evaluation of, 271
metabolite detoxification and excretion in, 490–491
nutritional management of, 485–501
Liver enzymes, in liver cancer, 429
Liver failure, acute, 437–460
clinicopathologic findings in, 443–445
cogulation studies in, 444–445
diagnosis of, 442–448
ancillary testing in, 446–447
histopathologic, 447–448
etiology of, 438–441
fluid therapy for, 451
general therapy for, 452–455
hepatotoxins and, 438–440
history in, 442
imaging techniques for, 445–446
liver function testing in, 445
major organ system support in, 449–451
management of, 448–456
nursing care for, 456
nutritional support for, 455–456
physical examination in, 442–443
urinalysis in, 444–445
fulminant, 351–352
Liver function testing, in acute liver failure, 445
in feline idiopathic hepatic lipidosis, 360
Lobular fibrosis, peripheral, 294
Lymphoma, hepatic, 420
radiographic appearance of, 426
Lymphosarcoma, feline, 295
hepatic, 323–324

Mannitol, for cerebral edema, 352
Manometry, in portal hypertension, 473
Melena, in feline idiopathic hepatic lipidosis, 365
Metabolic disease, and acute liver failure, 441
Methionine, avoidance of, in liver disease, 496
Metronidazole, for hepatic encephalopathy, 347
Micronutrients, in liver disease, metabolism of, 489–490
requirement for, 493–494
Minerals, in hepatic encephalopathy, 350–351
Monopty instrument, for liver biopsy, 284
Myelolipoma, liver, 423
Neomycin, for hepatic encephalopathy, 345–347
Neoplastic disease, and acute liver failure, 441
Neurologic system, support of, in acute liver failure, 450–451
Nursing care, for acute liver failure, 455–456
Nutrition, in acute liver failure, 455–456
in liver disease, 485–501
Paracentesis, for acute liver failure, 446
in portal hypertension, 471
for ascites, 478
Paraneoplastic syndromes, in liver neoplasia, 425
Parasitic infections, and acute liver failure, 440
Patent ductus venosus, imaging of, 315
Penicillamine, for copper-associated hepatopathies, 408–409
Pericholangitis, lesions of, 299
Peritoneovenous shunt, for ascites, in portal hypertension, 478
Phycomycosis, intestinal, with secondary liver disease, 270–271
Portal-azygos shunt, imaging of, 316
Portal clearance, tests of, 261–264
Portal-colic shunt, imaging of, 315
Portal hypertension, 461–483
consequences of, 466–468
diagnosis of, 468–473
clinical findings, 468–469
evaluation in, 469–473
imaging in, 472–473
laboratory findings, 469–472
diseases causing, 464–465
pathophysiology of, 462–464
prognosis in, 480
treatment of, 473–480
Portal vasculature, intrahepatic, imaging of, 314
Portal vein, ultrasound scan of, 320
Portal venography, in portal hypertension, 472
Portocaval anastomosis, for ascites, in portal hypertension, 479–480
Portosystemic anastomosis, for ascites, in portal hypertension, 479
Portosystemic shunt, canine, case study of, 267–269
imaging of, with radiographic contrast, 314
ultrasonographic findings in, 332
with portal hypertension, 466
Potassium, for hepatic encephalopathy, 346
Propranolol, for portal hypertension, 474
Protein(s), dietary, in feline idiopathic hepatic lipidosis, 362–363
in hepatic encephalopathy, 349
in liver disease, metabolism of, 487–489
requirement for, 492–493
liver synthesis of, 488
Renal system, support of, in acute liver failure, 450
Respiratory system, support of, in acute liver failure, 449
Scintigraphy, in portal hypertension, 472
Serum urea nitrogen, in liver disease, 265
Skye terrier, chronic active hepatitis in, 399
Copper-associated hepatopathy in, 413
Spironolactone, for ascites, in portal hypertension, 476
Temno needle, for liver biopsy, 284
2,3,2-Tetramine, for copper-associated hepatopathies, 409–410
Transaminases, in liver disease, 258
Trientine, for copper-associated hepatopathies, 409
Triglycerides, increased mobilization of, in feline idiopathic hepatic lipidosis, 367–368
Tru-Cut biopsy needle, 279–280

Ultrasonography, abdominal, for acute liver failure, 445–446
  hepatic imaging with, 317–327
  in liver biopsy, 281–285
  in liver neoplasia, 425
  in portal hypertension, 472
Urea cycle, of cat, 369
Urinalysis, in acute liver failure, 444–445
  in feline idiopathic hepatic lipidosis, 360
Ursodeoxycholate, for long-term liver disease, 510
  for primary biliary cirrhosis, 510
  for primary sclerosing cholangitis, 510–511
  mechanism of action of, 511–513
  toxicity of, 509
Ursodeoxycholic acid, for cholestatic long-term hepatitis, 511
  for feline idiopathic hepatic lipidosis, 366
  for gallstones, 378

Vascular resistance, increased, and portal hypertension, 464–465

Vasoconstrictors, for portal hypertension, 474
Vasodilators, for portal hypertension, 474
Viral infections, and acute liver failure, 440
Vitamin(s), in hepatic encephalopathy, 350
Vitamin E, for copper-associated hepatopathies, 410
Vitamin K, for hemorrhage, in acute liver failure, 454
  metabolism of, in liver disease, 490
Vomiting, in feline idiopathic hepatic lipidosis, 365
von Willebrand’s disease, prevalence by breed, 277

West Highland white terrier, chronic active hepatitis in, 391–392
  copper-associated hepatopathy in, 412–413
Wilson’s disease, copper metabolism in, 402

Zinc, for copper-associated hepatopathies, 406–408